PMID- 37413933 OWN - NLM STAT- MEDLINE DCOM- 20230825 LR - 20230825 IS - 1878-1705 (Electronic) IS - 1567-5769 (Linking) VI - 122 DP - 2023 Sep TI - Evaluation of autoantibody profile in healthy subjects after mRNA vaccination against COVID-19. PG - 110592 LID - S1567-5769(23)00917-7 [pii] LID - 10.1016/j.intimp.2023.110592 [doi] AB - BACKGROUND: SARS-CoV-2 severe acute respiratory syndrome has rapidly spread worldwide since 2019. All scientific and technological forces have concentrated towards the formulation of vaccines to contain the disease. In less than one year (December 2020) a first messenger RNA vaccine (Comirnaty, BioNTech/Pfizer) was authorized. However, the research community has wondered about possible side effects on the immune system, given the vaccines administration in phase 4. AIM: This study aims to evaluate the mRNA vaccine impact on the development of possible positive autoantibody profile in healthcare workers without any previous underlying pathology, after first, second and booster dose of Pfizer vaccine, by determining: circulating immune complexes concentrations (CIC); anti-myeloperoxidase (MPO) and anti-proteinase 3 (PR3) autoantibodies, the presence of antinuclear antibodies (ANA) and subsequent second level tests (extractable nuclear antigen (ENA) screen, double-strand DNA, extractable nuclear antigen (ANA) profile). METHODS: The subjects were divided according to anti-SARS-CoV-2 IgG RBD antibodies increasing concentrations in: Group I < 10 BAU/ml (N = 114); Group II > 1000 BAU/ml (N = 112); Group III > 2500 BAU/ml (N = 78). RESULTS: Our data show no autoreactive response changes over time in healthy subjects after vaccination. In fact, evaluation of ANA, CIC, anti-MPO, anti-PR3 and the detection of specific autoantigens, did not display significant variations. CONCLUSIONS: The results suggest the exclusion of a correlation between the administration of the vaccine and the possible onset of autoimmune disorders. Nevertheless, further investigations will be needed to test for any long-term side effects on an ever-growing population. CI - Copyright (c) 2023 The Authors. Published by Elsevier B.V. All rights reserved. FAU - Fiorelli, Denise AU - Fiorelli D AD - Department of Experimental Medicine, University of Tor Vergata, Rome, Italy. Electronic address: denise.fiorelli@ptvonline.it. FAU - Caruso, Vincenza AU - Caruso V AD - Department of Experimental Medicine, University of Tor Vergata, Rome, Italy. FAU - Belardi, Riccardo AU - Belardi R AD - Department of Experimental Medicine, University of Tor Vergata, Rome, Italy. FAU - Bernardini, Sergio AU - Bernardini S AD - Department of Experimental Medicine, University of Tor Vergata, Rome, Italy. FAU - Nuccetelli, Marzia AU - Nuccetelli M AD - Department of Experimental Medicine, University of Tor Vergata, Rome, Italy. LA - eng PT - Journal Article DEP - 20230703 PL - Netherlands TA - Int Immunopharmacol JT - International immunopharmacology JID - 100965259 RN - 0 (Autoantibodies) RN - 0 (Antibodies, Antinuclear) RN - 0 (Antibodies, Viral) RN - 0 (Antigens, Nuclear) SB - IM MH - Humans MH - *Autoantibodies MH - *COVID-19/prevention & control MH - Healthy Volunteers MH - SARS-CoV-2 MH - Vaccination MH - Antibodies, Antinuclear MH - Antibodies, Viral MH - Antigens, Nuclear OTO - NOTNLM OT - Autoantigens OT - Autoimmune disorders OT - COVID-19 OT - mRNA vaccine COIS- Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. EDAT- 2023/07/07 01:05 MHDA- 2023/08/25 06:42 CRDT- 2023/07/06 18:09 PHST- 2023/04/06 00:00 [received] PHST- 2023/06/16 00:00 [revised] PHST- 2023/06/30 00:00 [accepted] PHST- 2023/08/25 06:42 [medline] PHST- 2023/07/07 01:05 [pubmed] PHST- 2023/07/06 18:09 [entrez] AID - S1567-5769(23)00917-7 [pii] AID - 10.1016/j.intimp.2023.110592 [doi] PST - ppublish SO - Int Immunopharmacol. 2023 Sep;122:110592. doi: 10.1016/j.intimp.2023.110592. Epub 2023 Jul 3.